Podcasts about vanguards

“It’s designed to be simple in a way, even though it’s an incredibly complex device”, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its Dexter Robotic Surgery System and single-use instrument platform differentiates itself from others in the robotic market and how it can shorten the learning curve that can increase adoption of robots in ambulatory surgical centers.See omnystudio.com/listener for privacy information.

“If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly” says restor3D’s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implants, outlining how the win then for the surgeon is the capacity to complete more cases, with better patient outcomes reputationally, and the win for the facility is getting another case into the operating room. The in-depth interview covered restor3D’s AI planning and 3D printing capabilities, its path in integrating the Conformis acquisition to allow it to compete against larger companies in the knee-replacement market and the upcoming launch of its patient app. He also discussed how his drive to use technology to solve problems led him from the consulting world to leading medtech companies. Listen to this episode on Apple Podcasts and Spotify. See omnystudio.com/listener for privacy information.

KBThaBandhead, is back at it again with a new episode recapping the Santa Clara Vanguards' 2018 DCI  "Bayblon" performance. He gives his take on the field show and the execution of the arrangements Make sure you SUBSCRIBE for more Podcasts!   Website: https://www.bskillzentertainment.com/ Watch my REACTIONS on YouTube: https://www.youtube.com/c/kbthabandhead Instagram: https://www.instagram.com/kbthabandhead/ TikTok: https://www.tiktok.com/@kbthabandhead?lang=en Merch: https://kbthabandhead.myspreadshop.com/

"They drilled right through the little bunny's head!" The record box steers this show in a Funkier direction than the average episode of That Driving Beat. You'll hear late 1960s and early 1970s funky movers from Clarence Reid, Sir Joe Quarterman & Free Soul, Candi Staton, Ohio Players, Swamp Dogg (of course!), Junior & The Classics, Indianapolis's The Vanguards, and more. Plus, we've got funky covers of a country classic, a classic film theme, and a Creedence Clearwater Revival song! -Originally broadcast June 7, 2026- Booker T. Averhart & The Mustangs / Take Your Shoes Off (Part 1) - BONUS SONG!?Willie Mitchell / That Driving BeatThe Interpretations / Soul AffectionClarence Reid / Till I Get My ShareSir Joe Quarterman & Free Soul / (I Got) So Much Trouble In My Mind Pt. 1Paul Humphrey & His Cool Aid Chemists / DetroitCornelius Brothers & Sister Rose / Treat Her Like a LadyLeon Thomas / L-O-V-EDanny White / Natural Soul BrotherChuck Bernard / Hobo FlatsNatural Gas / What Do You Want From My LifeBill Withers / HarlemCandi Staton / Do It In the Name of LoveOhio Players / Pain (Part 1)Garland Green / I Can't Believe You Quit MeThe Bagdads / Green PowerSwamp Dogg / Do You BelieveDoris Duke / How Was I to Know You CaredSyl Johnson / Try MeThe Bar-Kays / Midnight CowboyLenny Williams / Feelin' BlueThe Staple Singers / I'll Take You ThereJunior & The Classics / Kill the PainThe Vanguards / The Thought of Losing Your LoveThe Honey Drippers / Impeach the PresidentFreddy-Henchi & the Soulsetters / Folsom PrisonDennis Coffey & The Detroit Guitar Band / ScorpioErrol Gaye and the Imaginations / Love and AffectionLittle Eva Harris / Mr. EverythingJames Brown and the Famous Flames / Shhhhhhhh (For a Little While)Fred Wesley & The J.B.'s / Doing It to DeathRotary Connection / Love Me NowTony Owens / Got'a Get My Baby Back Home Hosted on Acast. See acast.com/privacy for more information.

“Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It’s because the mortality doesn’t change, the use of resources skyrockets, but the mortality doesn’t change. In this country, every blind patient costs over $66,000 a year,” says Pravin Dugel, CEO of Ocular Therapeutix. “If we reduce that dropout rate by even 10% with Axpaxli, and I’m sure we’ll do even better, we’re talking about a quarter million fewer patients in this country alone who will not go blind. The impact of that, not just on a human basis but on an economic basis, is astronomical.” In this episode of the Vanguards of Healthcare podcast, Pravin sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk to discuss how the company can reduce the therapeutic and economic burden of retinal diseases.See omnystudio.com/listener for privacy information.

“We’re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,” IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio monitoring platform provides an end-to-end solution to monitor patients without disrupting their everyday lives, and its strategy to expand into the primary care setting to provide a more proactive approach to detect cardiac arrhythmias and other health signals. Listen to this episode on Apple Podcasts and Spotify.See omnystudio.com/listener for privacy information.

Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,” Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Healthcare episode, LaViolette sits down with BI analyst Matt Henriksson for an in-depth interview about the potential benefits of nanosecond ablation technology to treat atrial fibrillation, which combines an ultrashort pulse duration with a high amplitude of voltage. LaViolette also discusses the commercial strategy behind the launch of its NANOPULSE-AF IDE pivotal study, following promising first-in-human trial results.See omnystudio.com/listener for privacy information.

“I think this is going to be the most eventful ASCO for biotech in a while,” says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast to break down biotech’s rebound, why fundamentals may finally be improving after a prolonged bear market and how China’s speed and cost advantages are reshaping global drug discovery. They also explore AI’s potential to improve clinical success rates, rare-disease regulatory flexibility and why oncology, neuropsych and immunology remain fertile ground for innovation.See omnystudio.com/listener for privacy information.

Indianapolis-based rapper, musician, and writer Foosie discusses his debut album, “All-American Ghetto.” The album draws on his life — from growing up in Indianapolis' Mapleton-Fall Creek neighborhood to serving a 20-year prison sentence. During his incarceration, he learned to play acoustic guitar and developed his voice as a writer through the Indiana Prison Writers Workshop. In this conversation, Foosie reflects on that journey — and on the music and family that shaped him, including his uncle, Vonzell Wheeler of the legendary Naptown soul group The Vanguards.

“More than half of your time as a public company CEO is devoted to things that are not drug development,” Xontogeny CEO Chris Garabedian says. Garabedian joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain why he earlier left the track of operating public companies to back biotech, where better decisions can create the biggest value inflections. He discusses what separates real drug developers from scientists, why early biotech mistakes are often irreversible, how Xontogeny evaluates new companies, and why AI may improve research tools faster than it transforms human biology.See omnystudio.com/listener for privacy information.

“In biotech, all of the ideas sound amazing and most of them don’t work.” Roivant CEO Matt Gline joins Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast to explain how the company tries to tilt those odds through an unconventional model built around focused, entrepreneurial “vants.” Gline discusses why Roivant targets overlooked or deprioritized large-pharma assets, how its structure is designed to preserve speed and accountability, and why clinical rigor, capital allocation and disciplined execution matter more than biotech hype. The conversation also explores orphan-style launches, FDA consistency, AI and the challenge of building durable value in a volatile biotech market.See omnystudio.com/listener for privacy information.

“In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,” says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire’s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women’s health, the evolving AI landscape and the personal values — integrity, work ethic and mission — that shape how she invests and leads.See omnystudio.com/listener for privacy information.

“Nothing excites me as much as the potential for AI,” Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&D leader, explains why today’s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient stratification can transform target selection, drug creation and trials. Tessier-Lavigne also details why Xaira is chasing “high-hanging fruit,” the hard-to-drug targets others can’t reach, and what it will take to reverse Eroom’s Law.See omnystudio.com/listener for privacy information.

“IVL in general is an enabler for physicians to do very complex procedures — it’s simple, it’s easy to use and it’s safe. So even a physician that doesn’t have a lot of experience doing complex cases can now treat patients that they previously weren’t treating,” AVS Pulse Chairman Mark Toland tells Bloomberg Intelligence, referring to calcified arterial lesions in peripheral artery disease. In this Vanguards of Health Care episode, Toland joins BI analyst Matt Henriksson to discuss how the Pulse intravascular lithotripsy (IVL) system is differentiated vs. current technology, aiming to make treatment more flexible. He also highlights clinical results from the POWER PAD II pivotal trial, the commercial strategy ahead of FDA approval, and the expanding opportunity as aging demographics drive more hardened lesions that require IVL.See omnystudio.com/listener for privacy information.

“I wake up every day wanting to make health care better,” says Halle Tecco, founder of Rock Health and author of Massively Better Healthcare. Tecco joins Bloomberg Intelligence analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast to reflect on digital health’s evolution — from her early days at Apple’s App Store to building one of the sector’s first venture funds. She explains why Covid reset adoption curves, how hospitals became leading tech buyers and why aligning “margin and mission” now shapes her investment lens. Tecco also shares lessons from backing a laundry list of well-known startups, teaching at Columbia and Harvard, and why she wrote a book to empower the next wave of innovators.See omnystudio.com/listener for privacy information.

“Being privately held and being a pure play spine company has given us the focus, the resourcing and the investment we need to, to really take this thing and make it hum,” Highridge’s CEO Rebecca Whitney says about the 7th largest spine company. In this Vanguards of Health Care episode, Whitney sits down with BI analyst Matt Henriksson for an in-depth interview about the path to a private company from a subsidiary under a major, publicly traded ortho company. As an independent company, she explains how it can be nimble in M&A, including the acquisition of key expandable spinal implants from Accelus and the recent PathKeeper agreement, both of which augment Highridge’s portfolio that houses its Mobi-C cervical disc replacement system and Tether motion preservation system. She also explains the importance of saying yes to new roles to build your career trajectory.See omnystudio.com/listener for privacy information.

“We’re going to continue to drive innovation across the entire product portfolio, which also includes how we manufacture sensors,” Dexcom CEO Jake Leach tells Bloomberg Intelligence, outlining the company’s strategy to expand the use of continuous glucose monitors to more diabetic patients and beyond. In this Vanguards of Health Care podcast episode, Leach joins BI analyst Matt Henriksson for an in-depth discussion on Dexcom’s transition to the G7 15 Day sensor, aimed to reduce the frequency of changing sensors, as well as clinical data efforts to expand reimbursement to diabetic patients not on insulin and updates on the next-generation G8. He also reflects on his 22-year journey at Dexcom, rising from an engineer on a 30-person team to CEO of an 11,000-employee company.See omnystudio.com/listener for privacy information.

“We’re empowering health-care providers with unprecedented clinical depth in a compact portable form factor,” AliveCor CEO Priya Abani says about the development of its AI-enabled electrocardiogram (ECG) sensors, which provide medical-grade heart data anytime and anywhere. In this Vanguards of Health Care episode, Abani sits down with BI analyst Matt Henriksson for an in-depth discussion about the expansion of AliveCor’s Kardia 12L device, which gives physicians a smaller, more portable ECG option. The company has widened the device’s indications to 39 cardiac conditions, established a new Category III reimbursement code and continues to train its algorithm using 1 million ECGs. Abani also talks about how her time at Amazon.com influenced her perspective on the interaction of technology and the human experience.See omnystudio.com/listener for privacy information.

“One of our busy surgeons said, when they do an aprevo procedure, it’s a boring day in the OR and that’s actually a good thing,” Carlsmed’s CEO Mike Cordonnier tells Bloomberg Intelligence, as he explains how the use of AI technology is the future for spine procedures. In this Vanguards of Health Care episode, Cordonnier sits down with BI analyst Matt Henriksson for an in-depth interview about the design of the aprevo system, with its customized implants. He dives further into how aprevo reduces planning time, provides better alignment and lowers revision rates, creating favorable economics for hospitals. Other highlights from the episode include how he combined his experience across medtech and software to build this novel AI approach.See omnystudio.com/listener for privacy information.

“Now we’re seeing how there are new medicines that act directly on the heart itself and less on downstream consequences of heart disease,” says Robert Blum, president and CEO of Cytokinetics. On this episode of Vanguards of Health Care, Blum speaks with Bloomberg Intelligence analyst Andrew Galler about Cytokinetics’ transition to a commercial-stage company following the approval of Myqorzo, its competitive positioning in the obstructive hypertrophic cardiomyopathy market, and its potential to differentiate from competitors with upcoming ACACIA-HCM data. They also discuss Cytokinetics’ pipeline, which includes multiple assets targeting heart failure.See omnystudio.com/listener for privacy information.

“Health care creates friction everywhere — copays, approvals, pre-authorizations — and none of that matters when someone you love needs help right now,” says Glen Tullman, CEO of Transcarent, in his return to the Vanguards of Health Care podcast to explain why speed, access and simplicity are existential issues in US health care. In a wide-ranging conversation with Bloomberg Intelligence analyst Jonathan Palmer, Tullman outlines Transcarent’s vision for delivering 24/7 care through an AI-first, mobile-native platform. He discusses why legacy navigation models fail consumers, how the Accolade acquisition accelerates Transcarent’s strategy and why WayFinding reframes benefits, clinical guidance and care delivery into a single real-time experience designed around human urgency — not the administrative process.See omnystudio.com/listener for privacy information.

“Revenue cycle is really about solving two problems: generating an accurate receipt and then jumping through the fifty hoops to get paid.” says Dr. Michael Gao, CEO of Smarter Technologies. In this episode of Vanguards of Health Care, Gao joins Bloomberg Intelligence analyst Jonathan Palmer to explain how AI is transforming hospital revenue cycle management (RCM). He walks through Smarter’s approach to clinical intelligence and automation, why AI works best as a first pass with human supervision, and how smarter workflows can lift margins for hospitals operating on razor-thin economics. The conversation also explores Smarter’s formation with New Mountain Capital and Gao’s mission to reduce the trillion-dollar burden of health care administration.See omnystudio.com/listener for privacy information.

“We were a very valuable deep-science company that had the wrong business strategy,” Zymeworks CEO Ken Galbraith tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. In discussing the company’s strategic reset, Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances innovation with capital discipline. The conversation covers zanidatamab’s path to market, lessons from partnering with Jazz and BeOne, the value of asymmetric antibody design and why retaining upside through milestones and royalties could reshape long-term value creation.See omnystudio.com/listener for privacy information.

Vanguards of Health Care: Penumbra Expands CAVT Awareness “With pulmonary embolism, just like with stroke and some other things, where there’s an acute moment usually happening — the patient’s not doing well, decompressing on the table — time matters a lot. And because of the STORM-PE trial, we have the data on what that device time is in a pretty rigorous randomized study. And it just doesn’t compare to anything else out there. It’s dramatically less”, Penumbra CEO Adam Elsesser explains to Bloomberg Intelligence. In this Vanguards of Health Care episode, Elsesser sits down with BI medical technology analyst Matt Henriksson for an in-depth interview on Penumbra and how computer-assisted vacuum thrombectomy (CAVT) technology continues to improve, cutting the time to remove the clot while limiting blood loss. He also dives deep into the clinical results of the STORM-PE randomized clinical study, highlighting how CAVT demonstrated superiority over the standard of care to treat pulmonary-embolism patients, and its partnership with the PERT Consortium to drive public awareness of the need to treat this devastating disease.See omnystudio.com/listener for privacy information.

“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we’re in a unique position where we can stay really hyper-focused on what we’re doing. I’m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they’re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva’s doing right.” In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.See omnystudio.com/listener for privacy information.

We describe the top five technology categories that are on the vanguard of driving PQC adoption. We describe what these categories have in common and how that results in early adoption of post quantum cryptography.

“AI agents are at the knee of the curve in terms of where things are headed,” says John Beadle, Aegis Ventures co-founder and managing partner. In this episode of the Vanguards of Health Care podcast, Beadle joins Bloomberg Intelligence analyst Jonathan Palmer to unpack Aegis’s thesis-driven approach to founding AI-native health-care companies. He details how its 14-system consortium sources problems directly from operators, why automation is the biggest near-term value driver and how ventures like Ascertain have emerged from that model. Beadle also discusses the evolving venture market, the rise of agentic AI and why his personal experiences, shaped by his mother’s medical journey, fuel his mission to make the system more accessible and equitable.See omnystudio.com/listener for privacy information.

All Chapters AI Contribution: Courtesy of Google NotebookLM

“In the case of iLet, we're going to say, this is how much insulin they're getting for what they consider to be a usual meal. And we learn that and we can set it that way. So we just take the responsibility of learning carb counting, which is really tough, off the user's plate. That's an extra level of automation that traditional pumps don't provide,” Beta Bionics CEO Sean Saint explains to Bloomberg Intelligence. In this episode of Vanguards of Health Care, Saint sits down with BI analyst Matt Henriksson for an in-depth interview about Beta’s iLet pump, designed to eliminate the human stress of making insulin dosing decisions. The conversation also touches on the company’s pay as you go strategy through the pharmacy channel and future product development, including the Mint patch pump.See omnystudio.com/listener for privacy information.

“If you’re not going overseas, you’re going out,” says Dr. Xingli Wang, Co-President of Fosun Pharma. He tells Bloomberg Intelligence’s Sam Fazeli how Fosun is transitioning from generics to novel medicines and positioning itself as a global innovator. With 90% of R&D now focused on oncology, autoimmune and neurodegenerative diseases, Wang details Fosun’s ambition to move from a China-based manufacturer to a multinational developer with true blockbuster potential. He also reflects on how disciplined capital investment, scientific partnerships and cultural persistence could make Fosun the “Takeda of China.”Listen to this episode of Vanguards of Health Care on Apple Podcasts and SpotifySee omnystudio.com/listener for privacy information.

Sure, we've reviewed the fastest World Tour aero road bikes and the newest gravel machines, but what about an off-road capable folding bike? Variety is the spice of life, and Velo tech editor Alvin Holbrook has been getting spicy on Brompton's G Line, a bike that should be more capable than any of the legendary UK brand's previous offerings, thanks to larger wheels and much better tires and brakes. Alvin rode the G Line on his usual gravel test loop and reports back on how it performed and what type of rider it makes the most sense for. Would you wear AI on your face? Josh Ross has been in the shape of Oakley's new – and very expensive – Vanguard glasses that come with a video camera, mic and headphones, and a connection to artificial intelligence that's ready to answer *almost* any question you might have. Josh answers our questions, without any AI help, about what the Vanguards are like to live with, why they might have the best mic and headphones for cycling, and explains how they can actually cost less than buying separate glasses, headphones, and a camera. Levy has that new bike fizz after buying an Allied Able and shares some of his early ride impressions, as well as how it compares to his much-loved Santa Cruz Stigmata that he's lived on for the previous two years. Is it love at first ride, or might there be some regrets? Further reading Q36.5's New Cold-Weather Jackets Fit Like A … Condom? How Strava Traded User Goodwill for Nothing Mathieu van der Poel Spotted on an Unreleased Canyon Prototype Road Bike. Here's What We Know. Vittoria's New Gravel Tire is Faster AND Better for the Environment | This Week in Bike Tech Can a Folding Bike Actually Handle Gravel? We Pushed the Brompton G Line to the Limit. Garmin Teamed Up With Oakley and Meta to Make Smart Glasses We Actually Want to Wear 0:00 Intro2:02 Alvin and Josh: Are the Meta x Oakley glasses good for cycling?30:00 Brompton G-Line41:20 Are the new Vittoria gravel tires greenwashing?46:35 Levy's new bike day!1:08:20 We want your input on a new Zwift ride!

“What you have to do in a market like that, where it’s highly genericized, is first you have to have a clinical differentiation,” says Richard Lowenthal, CEO of ARS Pharmaceuticals. “You have to have a benefit to the community, benefit to the patient population. Neffy achieves that very effectively by providing an option that’s very simple — it’s easy to carry, it’s very easy to use.” In this episode of Vanguards of Health Care, Richard sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the company has navigated the commercial launch of its needle-free epinephrine nasal spray, neffy, in a highly competitive genericized market.See omnystudio.com/listener for privacy information.

“In a world where we have so many wearables — smart rings, watches, glucose sensors — it’s challenging to integrate all of this information,” say Biolinq founder Jared Tangney and CEO Rich Yang. “So we decided to make it available to everybody in one device.” In this Vanguards of Health Care episode, the pair speak with Bloomberg Intelligence’s analyst Matt Henriksson about Biolinq’s microsensor-based patch that uses silicon semiconductor technology to track glucose and potentially other biomarkers. They also discuss the company’s commercial strategy for type 2 diabetes patients following its FDA de Novo approval, a US regulatory designation granted to first-of-its-kind medical devices that have been shown to be safe and effective.See omnystudio.com/listener for privacy information.

A whole bunch of new tracks to check out, loads of albums dropping these days. Jabs is back on deck with Oaks. Playlist: What Drives You by The Profit Menorah by Jackie Hill Perry & nobigdyl. Fair Warning by J.Solo ft. Knaladeus Keep Me First by Brinson ft. Dre Murray Power Moves by Vanguards, Mic Wise & Trutha ft. GB & Bill B. Vengeance II by Tae Lamar ft. MotionPlus, Propaganda & m1L HARD OUT HERE! by DJ Mykael V & Gavin the HotRod ft. Aable UNDER THE BLOOD by Basecamp (Procyse & Rich Colon) ft. Knaladeus Breathe In by Yasad One Close Call by m1L & iNTELLECT As The World Turns by Q-Flo & IAMOPB Glorious by Still Shadey Marz Barz III by R.kitect Boyz II Men by Jered Sanders Vote on the playlist at www.definitionradio.com/show/972 Leave your requests/shout-outs on our socials www.facebook.com/DefinitionRadio www.instagram.com/DefinitionHH www.twitter.com/DefinitionHH www.krosswerdz.com

“The same was in neuro intervention for aneurysms, it was open clipping or it was endovascular. And I think that’s what’s happening in BCI. So there’s a bunch of craniotomy-based, open BCI companies, and then there’s an interventional approach”, Synchron’s founder and CEO Tom Oxley explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Tom sits down with BI analyst Matt Henriksson for an in-depth interview about the company and how he utilized his experience with minimally invasive endovascular procedures to create its Stentrode as novel way to utilize brain-computer interfaces (BCI) without open brain surgery.See omnystudio.com/listener for privacy information.

“It’s hard to overemphasize how broken we are in how we care for older adults.” says Seth Sternberg, CEO of Honor. Sternberg joins Bloomberg Intelligence analyst Jonathan Palmer to unpack how Honor’s AI-driven logistics and the Home Instead network tackle the hardest problem in home care: scaling quality. In this episode of the Vanguards of Health Care podcast they dive into matching the right caregiver to the right client, why stability is the No. 1 caregiver need, franchise advantages, and making private‑pay care more affordable for the middle class plus how quality metrics and “defect rates” power growth.See omnystudio.com/listener for privacy information.

“When we talk about spine, having 7D, which is a highly differentiable product for deformities, I think it’s giving us the basis to become a real player and help to solve the most complex issues into spine,” Orthofix’s CEO Massimo Calafiore says as he explains the future of spine navigation. In this Vanguards of Health Care episode, Calafiore sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about the benefits of its 7D navigation in spine procedures that utilizes camera-based technology combined with machine-vision algorithms, the growth opportunities in specialized orthopedics, including limb preservation and extremity deformity correction, and how he built a new management team from the ground up to tackle these opportunities. See omnystudio.com/listener for privacy information.

“We thought that the folks would only turn on stimulation when they felt faint or lightheaded, but in fact, they’re using the stimulation the entire waking day because the stimulation is stabilizing their blood pressure, more oxygenation is reaching their brain,” Onward Medical CEO Dave Marver explains in this Vanguards of Health Care podcast episode. Marver sits down with Bloomberg Intelligence analyst Matt Henriksson for an in-depth interview about Onward and how its developments differ from other companies that utilize brain-computer interfaces (BCI) by connecting BCI technology to its ARC platform to stabilize blood pressure and restore movement of the human body, instead of simply using the patient’s thoughts to control computer functions. Marver also discusses the initiation of its Empower BP Pivotal study to assess the use of its ARC-IM system to address blood-pressure instability after spinal cord injuries (SCI).See omnystudio.com/listener for privacy information.

“Doctors don’t want pharma reps to buy them dinner, right? They don’t. They want help in the five minutes that really matter,” Viz.ai’s CEO Chris Mansi and Salesforce’s Frank Defesche explain in this Vanguards of Health Care podcast episode. Mansi and Defesche sit down with Bloomberg Intelligence analyst Matt Henriksson to talk about Viz.ai and its agentic AI platform that connects medical scans and images to the right diagnosis and treatment guidelines. Also tune in to learn how the Viz.ai platform aims to partner with Salesforce’s life-science division to improve pharmaceutical point-of-care workflow while providing more personalized care.See omnystudio.com/listener for privacy information.

The "Vanguards" change to Squadron organisation is coming in less than a week. Meanwhile, Community Goal records are tumbling, with additional Rail Guns rewards unlocked.

The Galaxy is no longer suffering from flickering shadows, judging by early observations. And an updated version of Squadrons has been released, bringing Squadron Carriers and the ability to transfer credits directly to other Commanders in the same Squadron.

We finally have time to talk about the Vanguards update, and have many thoughts about a very content heavy week!Elite Dangerous Vanguards Patch 2 – https://forums.frontier.co.uk/threads/elite-dangerous-vanguards-patch-2.640923/Mystery to be unlocked – https://canonn.science/codex/a-secret-to-be-uncovered-a-trail-to-be-followed/Community NewsFan made colonisation map – https://oasis-cartograph.onrender.com/Alec's colonisation systems forum thread – https://forums.frontier.co.uk/threads/alecs-guide-to-interesting-colonisation-systems-and-stations.638893/#post-10659743

The crew discuss the latest update, Vanguards and Shadows, and reflect on a fantastic ECM. Community News:“Ludicrous! The Drakhyr Rally” by Cmdr Homborger -https://edrushfleet.co.uk/2025/08/19/ludicrous-the-drakhyr-rally/“A Valley of Ice and Sand” (Out There) by Commander Exorcist - https://youtu.be/u9kS-xiYcoU“Elite Dangerous: Odyssey - Exploration Montage | Episode 19” by coeneman02 - https://youtu.be/d4k-440dchk“Doing this made Elite Dangerous So much better !” by Erad*Prime - https://youtu.be/ufPO-FLR-X8“SPECIAL Elite Dangerous: Corsair Mass Meet Up” by The Buur Pit - https://youtu.be/4lRd6mTZj0Ehttps://edastro.com/galmap/#-366,0,436,6Alec's annotated map: https://i.imgur.com/6LjTfoj.png Download the episode directly from here

The crew fight latency issues and discuss their favourite of the last six ships introduced to the game.

The bulk of today's show is spent talking about the Panther Clipper, how does it measure up to expectations? Our bumper sized crew have thoughts!

This week's headline reads like a financial horror story — and unfortunately, it's a true one.

The crew discuss the upcoming Vanguards update and catch up on the last two weeks after an amazing interview with Arthur!

The crew discuss the upcoming Vanguards update and catch up on the last two weeks after an amazing interview with Arthur!

The crew look to the next Frontier Unlocked and speculate what will be revealed as part of the Vanguards update

JR has drummed on over 200 US Billboard Hot 100 songs and 50 Grammy winning tunes. He was in Rufus w/ Chaka Khan in the late 70s/early 80s, has released two solo albums, written for soundtracks, produced other artists, and has led various combos over the years. He is currently promoting his auto-biography King of the Groove. We discuss "Gonna Be Alright" from The Bronx, USA soundtrack (2020), "Flight 81" from his first solo album, Funkshui (2004), and "You're Really Out of Line" by Rufus from Seal in Red (1983). End song: "Tal Shia" by SRT from Vanguards of Groove (2023). Intro: "Higher Love" by Steve Winwood (1986). More at johnjrrobinson.com. Hear more Nakedly Examined Music. Support us on Patreon.